Charles Schwab’s Oramed Pharmaceuticals ORMP Stock Holding History

Charles Schwab’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-83,219	Closed	-$720K	–	3617
2022 Q1	$720K	Buy	83,219 +17,512	+27%	+$179K	﹤0.01%	2981
2021 Q4	$939K	Buy	65,707 +1,456	+2%	+$30.4K	﹤0.01%	2940
2021 Q3	$1.41M	Buy	64,251 +7,609	+13%	+$130K	﹤0.01%	2769
2021 Q2	$758K	Buy	+56,642	New	+$648K	﹤0.01%	3024

Other funds holding ORMP

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Charles Schwab's ORMP Position: Q2 2022 in Review

Charles Schwab sold out of Oramed Pharmaceuticals (ORMP) in Q2 2022, closing a stake of 83,219 shares — an estimated $720K sold.

Charles Schwab first reported a position in ORMP in Q2 2021 and held it in 4 quarters. The position peaked at $1.41M in Q3 2021. 88 funds tracked by Wall St. Rank hold ORMP as of Q2 2022.

Charles Schwab reported no remaining Oramed Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Charles Schwab sold 83,219 Oramed Pharmaceuticals shares in Q2 2022, an estimated $720K.
Charles Schwab first reported a position in Oramed Pharmaceuticals in Q2 2021 and held it in 4 quarters.
Charles Schwab's Oramed Pharmaceuticals position peaked at $1.41M in Q3 2021.
88 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2022.

Based on Charles Schwab's 13F filing for Q2 2022, filed 15 Aug 2022.